VNDA Vanda Pharmaceuticals Inc

Price (delayed)

$6.21

Market cap

$373.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.05

Enterprise value

$326.46M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 36
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 20

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Highlights
The revenue has increased by 8% YoY
The gross profit has increased by 8% YoY
VNDA's quick ratio is down by 49% YoY and by 13% from the previous quarter
Vanda Pharmaceuticals's equity has decreased by 45% YoY and by 14% QoQ

Key stats

What are the main financial stats of VNDA

VNDA stock price

How has the Vanda Pharmaceuticals stock price performed over time
Intraday
2.64%
1 week
6.15%
1 month
1.31%
1 year
26.99%
YTD
-29.59%
QTD
1.47%

Financial performance

How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$217.78M
Gross profit
$205.1M
Operating income
-$160.36M
Net income
-$239.55M
Gross margin
94.2%
Net margin
-110%
The operating income has plunged by 121% YoY and by 6% from the previous quarter
VNDA's operating margin has shrunk by 104% YoY and by 5% QoQ
VNDA's net income is down by 9% since the previous quarter
VNDA's net margin is down by 8% since the previous quarter

Price vs fundamentals

How does VNDA's price correlate with its fundamentals

Growth

What is Vanda Pharmaceuticals's growth rate over time

Valuation

What is Vanda Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.31
P/S
1.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.5
The company's EPS fell by 8% QoQ
VNDA's P/B is 46% above its 5-year quarterly average of 0.9 and 19% above its last 4 quarters average of 1.1
Vanda Pharmaceuticals's equity has decreased by 45% YoY and by 14% QoQ
VNDA's P/S is 11% below its 5-year quarterly average of 1.9 and 6% below its last 4 quarters average of 1.8
The revenue has increased by 8% YoY

Efficiency

How efficient is Vanda Pharmaceuticals business performance
The company's return on sales has shrunk by 149% YoY and by 7% QoQ
Vanda Pharmaceuticals's ROIC has decreased by 29% from the previous quarter
Vanda Pharmaceuticals's return on equity has decreased by 25% QoQ
Vanda Pharmaceuticals's ROA has decreased by 19% from the previous quarter

Dividends

What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNDA.

Financial health

How did Vanda Pharmaceuticals financials performed over time
The total assets is 184% higher than the total liabilities
VNDA's quick ratio is down by 49% YoY and by 13% from the previous quarter
The current ratio is down by 45% year-on-year and by 10% since the previous quarter
VNDA's debt is 97% smaller than its equity
Vanda Pharmaceuticals's debt to equity has soared by 200% YoY and by 50% from the previous quarter
Vanda Pharmaceuticals's equity has decreased by 45% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.